Pharmacogenomics

[1]  National Human Genome Research Institute , 2020, Definitions.

[2]  Sephalie Y. Patel,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes , 2019, Clinical pharmacology and therapeutics.

[3]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update , 2019, Clinical pharmacology and therapeutics.

[4]  Chen Jiang,et al.  A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance) , 2018, Clinical pharmacology and therapeutics.

[5]  A. V. van Kuilenburg,et al.  DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. , 2018, The Lancet. Oncology.

[6]  L. Cavallari,et al.  Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent , 2018, JAMA.

[7]  S. Lévesque,et al.  ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein) , 2018, Circulation.

[8]  Yoshiro Saito,et al.  HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians , 2018, Clinical pharmacology and therapeutics.

[9]  J. Luzum,et al.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. , 2018, Pharmacogenomics.

[10]  K. Murray,et al.  Outpatient Opioid Prescriptions for Children and Opioid-Related Adverse Events , 2018, Pediatrics.

[11]  Richie Soong,et al.  Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial , 2018, BMC Medicine.

[12]  P. Schwartz,et al.  Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model , 2018, European heart journal.

[13]  C. Lewis,et al.  Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts , 2018, bioRxiv.

[14]  M. Relling,et al.  Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group , 2018, Clinical pharmacology and therapeutics.

[15]  Alexander E. Lopez,et al.  A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease , 2018, The New England journal of medicine.

[16]  Diego Ardissino,et al.  Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial. , 2018, Journal of the American College of Cardiology.

[17]  H. Nakagawa,et al.  Whole genome sequencing analysis for cancer genomics and precision medicine , 2018, Cancer science.

[18]  Joshua C Denny,et al.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. , 2018, JACC. Cardiovascular interventions.

[19]  Neil A. Miller,et al.  The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database , 2017, Clinical pharmacology and therapeutics.

[20]  L. Cavallari,et al.  Is universal HLA‐B*15:02 screening a cost‐effective option in an ethnically diverse population? A case study of Malaysia , 2017, The British journal of dermatology.

[21]  Jeffrey L. Anderson,et al.  Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial , 2017, JAMA.

[22]  E. Behr,et al.  Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study , 2017, Circulation.

[23]  Lisa Bastarache,et al.  Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. , 2017, Assay and drug development technologies.

[24]  M O Karlsson,et al.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.

[25]  M. Weale,et al.  Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? , 2016, The Pharmacogenomics Journal.

[26]  Michelle Whirl-Carrillo,et al.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, Genetics in Medicine.

[27]  M. Relling,et al.  Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease , 2016, Pediatrics.

[28]  J M Pulley,et al.  Physician response to implementation of genotype‐tailored antiplatelet therapy , 2016, Clinical pharmacology and therapeutics.

[29]  S. Haga,et al.  Considerations of pharmacogenetic testing in children. , 2016, Pharmacogenomics.

[30]  Melissa A. Basford,et al.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.

[31]  Mustafa Tekin,et al.  Next generation sequencing: implications in personalized medicine and pharmacogenomics. , 2016, Molecular bioSystems.

[32]  G. Stack,et al.  Warfarin Pharmacogenetics Reevaluated:  Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials. , 2016, American journal of clinical pathology.

[33]  Yuan Ji,et al.  Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. , 2016, The Journal of molecular diagnostics : JMD.

[34]  E. Pearson,et al.  Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents , 2016, Pharmacogenomics and personalized medicine.

[35]  Rajiv,et al.  Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. , 2016, The New England journal of medicine.

[36]  Alexander E. Lopez,et al.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.

[37]  D. Nickerson,et al.  Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting , 2016, Clinical pharmacology and therapeutics.

[38]  B. Franke,et al.  Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. , 2015, Gastroenterology.

[39]  S. Mallal,et al.  Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. , 2015, The Journal of allergy and clinical immunology.

[40]  N. Limdi,et al.  Race influences warfarin dose changes associated with genetic factors. , 2015, Blood.

[41]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[42]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[43]  J. Tardif,et al.  Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib , 2015, Circulation. Cardiovascular genetics.

[44]  Albert-László Barabási,et al.  Response to Letter of Correspondence – Bastiaens et al. , 2015, Nature Biotechnology.

[45]  M. Relling,et al.  Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Keith Marsolo,et al.  Practical considerations in genomic decision support: The eMERGE experience , 2015, Journal of pathology informatics.

[47]  B. Gage,et al.  Genotype and risk of major bleeding during warfarin treatment. , 2014, Pharmacogenomics.

[48]  P. Kwan,et al.  Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions , 2014, Neurology.

[49]  John Spertus,et al.  Inactivating mutations in NPC1L1 and protection from coronary heart disease. , 2014, The New England journal of medicine.

[50]  Munir Pirmohamed,et al.  Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. , 2014, Annual review of genomics and human genetics.

[51]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[52]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype , 2014, Clinical pharmacology and therapeutics.

[53]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[54]  D. Boudreau,et al.  Genetic Risk Factors for Major Bleeding in Patients Treated With Warfarin in a Community Setting , 2014, Clinical pharmacology and therapeutics.

[55]  Thomas Meitinger,et al.  Loss-of-function mutations in SLC30A8 protect against type 2 diabetes , 2014, Nature Genetics.

[56]  D. Owens,et al.  Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome , 2014, Annals of Internal Medicine.

[57]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens , 2014, Clinical pharmacology and therapy.

[58]  N. Eriksson,et al.  A randomized trial of genotype-guided dosing of warfarin. , 2013, The New England journal of medicine.

[59]  Rita Barallon,et al.  A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. , 2013, The New England journal of medicine.

[60]  R. Califf,et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.

[61]  Erica A. Bowton,et al.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.

[62]  R. Altman,et al.  Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes , 2013, PloS one.

[63]  Y. Teerawattananon,et al.  Economic evaluation of HLA‐B*15:02 screening for carbamazepine‐induced severe adverse drug reactions in Thailand , 2013, Epilepsia.

[64]  Yusuke Nakamura,et al.  Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study , 2013, The Lancet.

[65]  Dan M Roden,et al.  Genome-wide association studies in pharmacogenomics: successes and lessons , 2013, Pharmacogenetics and genomics.

[66]  P. Deloukas,et al.  Mycobacterium bovis Requires P27 (LprG) To Arrest Phagosome Maturation and Replicate within Bovine Macrophages , 2013, BMC Genomics.

[67]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[68]  Justin Starren,et al.  Crossing the omic chasm: a time for omic ancillary systems. , 2013, JAMA.

[69]  B. Kuehn.  FDA: No codeine after tonsillectomy for children. , 2013, JAMA.

[70]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[71]  B. Ao,et al.  The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes , 2012, PharmacoEconomics.

[72]  Melissa A. Basford,et al.  Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.

[73]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[74]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[75]  Melissa A. Basford,et al.  Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. , 2012, Pharmacogenomics.

[76]  M. Pencina,et al.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. , 2011, JAMA.

[77]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[78]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[79]  C. Landrigan,et al.  Temporal trends in rates of patient harm resulting from medical care. , 2010, The New England journal of medicine.

[80]  Marylyn D. Ritchie,et al.  Abstract 19509: Identifying Genotype-Phenotype Relations in Electronic Medical Record Systems: Application to Warfarin Pharmacogenomics. , 2010 .

[81]  Issam Zineh,et al.  DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. , 2010, Pharmacogenomics.

[82]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[83]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[84]  Cheng Cheng,et al.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Fernando Rivadeneira,et al.  A genome-wide association study of acenocoumarol maintenance dosage. , 2009, Human molecular genetics.

[86]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[87]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[88]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[89]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[90]  R. Walensky,et al.  The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV , 2008, AIDS.

[91]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[92]  M. Rieder,et al.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.

[93]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[94]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[95]  R. Desnick,et al.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. , 2008, American journal of human genetics.

[96]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[97]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[98]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[99]  S. Ellenberg.  Food and Drug Administration (FDA) , 2005 .

[100]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[101]  V. Armstrong,et al.  Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B, and *3C. , 2004, Clinical chemistry.

[102]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[103]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[104]  J. Ablin,et al.  Warfarin therapy is feasible in CYP2C9*3 homozygous patients. , 2004, European journal of internal medicine.

[105]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[106]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[107]  B. Pomeranz,et al.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. , 1998, JAMA.

[108]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[109]  A. Motulsky.  Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.

[110]  Table of Pharmacogenomic Biomarkers in Drug Labeling , 2015 .

[111]  P. Whiting,et al.  Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. , 2014, Health technology assessment.

[112]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[113]  P. Mangin,et al.  Usefulness of postmortem biochemistry in forensic pathology: illustrative case reports. , 2012, Legal medicine.

[114]  International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice. , 2008, Federal register.

[115]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[116]  W. Kalow,et al.  Unusual responses to drugs in some hereditary conditions , 1961, Canadian Anaesthetists' Society journal.

[117]  LETTERS TO THE EDITOR RE: CCNP POSITION PAPER ON THE USE OF PLACEBOS IN PSYCHIATRY , 2022 .